Literature DB >> 27609171

Comment on: A rare case of eyelid sarcoidosis presenting as an orbital mass.

Charudutt Kalamkar1, Nishant V Radke2, Amrita Mukherjee3, Snehal Nishant Radke4.   

Abstract

Entities:  

Mesh:

Year:  2016        PMID: 27609171      PMCID: PMC5026086          DOI: 10.4103/0301-4738.190170

Source DB:  PubMed          Journal:  Indian J Ophthalmol        ISSN: 0301-4738            Impact factor:   1.848


× No keyword cloud information.
Sir, With great interest, we read the article entitled, “A rare case of eyelid sarcoidosis presenting as an orbital mass” by Gaspar et al.[1] We have a few observations over which we request their comments. The title of the article presents this case as an eyelid mass due to sarcoidosis whereas, in fact, the text describes it as an orbital mass seen through eyelid. The coronal contrast-enhanced computed tomography (CECT) demonstrates inferior extraconal orbital mass lesion. A sagittal section image would have been useful to evaluate extension of mass toward the lower eyelid. The intraoperative description also mentions the mass to be arising from orbital floor and not arising from lid tissues. Sarcoidosis presenting as orbital mass is not uncommon. Orbital mass as presenting feature of sarcoidosis is found in up to 7% of patients. Orbital sarcoidosis commonly presents as palpable mass or as pseudotumor with inferior orbit being a common location of orbital sarcoidosis.[23] Most sarcoid lesions are found in extraconal anterior orbital space, which makes the lesion easily palpable or visualized early through the lid.[3] Eyelid involvement is described in 12-17% cases of orbital sarcoidosis.[23] We would like to know about the presence of any uveitis as the article fails to mention so. Uveitis is the most common finding of ocular sarcoidosis and has been demonstrated in 3-15% patients with orbital sarcoidosis.[234] Consistency of lesion or any change in lesion size with Valsalva has not been mentioned as the authors considered primary differential being orbital varix. CECT classically demonstrates hyperintense enhancement in case of varix with increase in size with post-Valsalva maneuver. In case thrombosed varix is suspected, magnetic resonance imaging with contrast and magnetic resonance angiography is a better imaging modality to differentiate vascular and nonvascular pathologies. We would like to know whether systemic steroid treatment was initiated modality after histological diagnosis of sarcoidosis. We agree with their advice of close follow-up since patients with orbital lesions as a presenting feature of sarcoidosis may develop systemic sarcoidosis or may have further progression of existing systemic lesions.[5] Postsurgery clinical picture and radiological (CECT) images would have been helpful.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  5 in total

Review 1.  Sarcoidosis and its ocular manifestations.

Authors:  J A Smith; C S Foster
Journal:  Int Ophthalmol Clin       Date:  1996

2.  Orbital and adnexal involvement in sarcoidosis: analysis of clinical features and systemic disease in 30 cases.

Authors:  Hakan Demirci; Murray D Christianson
Journal:  Am J Ophthalmol       Date:  2011-03-31       Impact factor: 5.258

3.  Orbital and adnexal sarcoidosis.

Authors:  Venkatesh C Prabhakaran; Perooz Saeed; Bita Esmaeli; Timothy J Sullivan; Alan McNab; Garry Davis; Alejandra Valenzuela; Igal Leibovitch; Anat Kesler; Jennifer Sivak-Callcott; Erika Hoyama; Dinesh Selva
Journal:  Arch Ophthalmol       Date:  2007-12

4.  A rare case of eyelid sarcoidosis presenting as an orbital mass.

Authors:  Balan Louis Gaspar; Kirti Gupta; Usha Singh
Journal:  Indian J Ophthalmol       Date:  2016-03       Impact factor: 1.848

5.  Outcome of the treatment for sarcoidosis.

Authors:  G W Hunninghake; S Gilbert; R Pueringer; C Dayton; C Floerchinger; R Helmers; R Merchant; J Wilson; J Galvin; D Schwartz
Journal:  Am J Respir Crit Care Med       Date:  1994-04       Impact factor: 21.405

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.